Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and | Svizzera | Salute | Prodotti farmaceutici | 642,13 Mrd CHF | 84,5x | 1,25 | 715 CHF | 3,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Roche Holding | Svizzera | Salute | Prodotti farmaceutici | 216,25 Mrd CHF | 19,2x | -5,89 | 272,40 CHF | 0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 5,7% Rialzo | Fai l’upgrade a Pro+ | |
Roche Holding Participation | Svizzera | Salute | Prodotti farmaceutici | 203,66 Mrd CHF | 20,4x | -5,89 | 256,60 CHF | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 13,9% Rialzo | Fai l’upgrade a Pro+ | |
Novartis | Svizzera | Salute | Prodotti farmaceutici | 177,58 Mrd CHF | 11,3x | 0,13 | 89,02 CHF | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 20,7% Rialzo | Fai l’upgrade a Pro+ | |
Novartis | Svizzera | Salute | Prodotti farmaceutici | 177,58 Mrd CHF | 11,3x | 0,13 | 88,98 CHF | 0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Sandoz | Svizzera | Salute | Prodotti farmaceutici | 16,31 Mrd CHF | -2.379,2x | 22,29 | 37,54 CHF | 1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 14,7% Rialzo | Fai l’upgrade a Pro+ | |
Siegfried Holding Ltd | Svizzera | Salute | Prodotti farmaceutici | 4,24 Mrd CHF | 32,8x | -2,26 | 993 CHF | 0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 17,4% Rialzo | Fai l’upgrade a Pro+ | |
Galenica Sante | Svizzera | Salute | Prodotti farmaceutici | 3,73 Mrd CHF | 21,1x | -0,64 | 75,05 CHF | 0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 3,2% Rialzo | Fai l’upgrade a Pro+ | |
Dottikon Es Holding AG | Svizzera | Salute | Prodotti farmaceutici | 3,09 Mrd CHF | 40,9x | -3,24 | 223,50 CHF | 1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Joincare Pharmaceutical DRC | Svizzera | Salute | Prodotti farmaceutici | 2,54 Mrd CHF | 14,7x | 4,91 | 7,22 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
COSMO Pharma | Svizzera | Salute | Prodotti farmaceutici | 1,03 Mrd CHF | 15,8x | 0,03 | 64,20 CHF | 0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 39,6% Rialzo | Fai l’upgrade a Pro+ | |
PolyPeptide Group AG | Svizzera | Salute | Prodotti farmaceutici | 936,73 Mln CHF | -35x | -1,63 | 29,25 CHF | 3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 17,6% Rialzo | Fai l’upgrade a Pro+ | |
Santhera Pharmaceuticals Holding | Svizzera | Salute | Prodotti farmaceutici | 177,96 Mln CHF | 2,5x | 0,01 | 14,46 CHF | 4,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Curatis Holding | Svizzera | Salute | Prodotti farmaceutici | 61,05 Mln CHF | -0,1x | 12,60 CHF | -3,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Spexis | Svizzera | Salute | Prodotti farmaceutici | 4,74 Mln CHF | -0,2x | -0,06 | 0,07 CHF | 16,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |